Supernus announced that the FDA has approved the supplemental New Drug Application for Oxtellar XR (oxcarbazepine) to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.
Ook interessant voor je
Supernus announced that the FDA has approved the supplemental New Drug Application for Oxtellar XR (oxcarbazepine) to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![[onderzoek] Marketeers balanceren tussen AI en authentieke merkbeleving](https://www.pharmamarketeer.nl/wp-content/uploads/2025/03/167284-80x60.jpg)
